

SUPPLEMENT

TABLE S1. SUMMARY OF ALL RECORDED TREATMENT TOXICITIES WITH RESPECTIVE GRADES

GRADE	NUMBER OF AES: N(%)	TYPE OF AES : N(%)			
G1	437 (67.6%)	Cystitis noninfective	75 (17.2%)	Nausea	3 (0.7%)
		Diarrhea	73 (16.7%)	Fatigue	11 (2.5%)
		Urinary urgency	10 (2.3%)	Testicular pain	2 (0.5%)
		Urinary frequency	71 (16.2%)	Penile pain	1 (0.2%)
		Urinary incontinence	12 (2.7%)	Urinary tract pain	4 (0.9%)
		Dysuria	18 (4.1%)	Dysaesthesia	1 (0.2%)
		Urinary tract obstruction	25 (5.7%)	Headache	1 (0.2%)
		Proctitis	48 (11%)	Back pain	2 (0.5%)
		Constipation	31 (7.1%)	Rectal pain	1 (0.2%)
		Abdominal pain	15 (3.4%)	Pelvic pain	2 (0.5%)
		Pain	1 (0.2%)	Insomnia	1 (0.2%)
		Haematuria	2 (0.5%)	Flatulence	6 (1.4%)
		Rectal haemorrhage	21 (4.8%)		
G2	164 (25.4%)	Rectal haemorrhage	5 (3%)	Haematuria	2 (1.2%)
		Urinary frequency	3 (1.8%)	Abdominal pain	2 (1.2%)
		Urinary tract infection	38 (23.2%)	Urethral infection	2 (1.2%)
		Urinary incontinence	13 (7.9%)	Constipation	1 (0.6%)
		Proctitis	35 (21.3%)	Flatulence	1 (0.6%)
		Cystitis noninfective	26 (15.9%)	Fecal incontinence	1 (0.6%)
		Diarrhea	7 (4.3%)	Urinary tract pain	3 (1.8%)
		Urinary tract obstruction	23 (14%)	Penile infection	1 (0.6%)
		Shingles	1 (0.6%)		
G3	40 (6.2%)	Urinary tract obstruction	26 (65%)	Proctitis	1 (2.5%)
		Urinary incontinence	2 (5%)	Urinary tract infection	1 (2.5%)
		Shingles	1 (2.5%)	Anaemia	1 (2.5%)
		Diarrhea	4 (10%)	Anorectal infection	1 (2.5%)
		Urinary fistula	1(2.5%)		
		Cystitis noninfective	2 (5%)		
G4	5 (0.8%)	Urinary tract obstruction		All 1 (20%)	
		Urinary fistula			
		Sepsis			
		Haematuria			
		Rectal haemorrhage			

TABLE S2. SUMMARY OF RT – RELATED \geq G2 SERIOUS ADVERSE EFFECTS

TYPE OF AES	N(%)
Urinary tract obstruction	29 (69%)
Urinary incontinence	1 (2.4%)
Urinary fistula	2 (4.8%)
Sepsis	1 (2.4%)
Cystitis noninfective	2 (4.8%)
Haematuria	1 (2.4%)
Proctitis	1 (2.4%)
Urinary tract infection	1 (2.4%)
Rectal haemorrhage	1 (2.4%)
Diarrhea	1 (2.4%)
Anaemia	1 (2.4%)
Anorectal infection	1 (2.4%)

TABLE S3. \geq G2 TOXICITY OCCURRENCE IN PATIENTS TREATED WITH ART COMPARED TO SRT

\geq G2 TOXICITY IN ART VS SRT GROUPS	HR*	95% CI FOR HR	P VALUE
acute GI	1.72	(0.77 – 3.83)	0.18
acute GU	0.93	(0.49 – 1.74)	0.81
late GI	0.81	(0.35 – 1.90)	0.63
late GU	1.28	(0.70 – 2.35)	0.42

* REFERENCE POINT-ART

TABLE S4. ASSOCIATION BETWEEN \geq G2 TOXICITY OCCURRENCE AND TIME FROM RP TO RT

\geq G2 TOXICITY AND TIME TO RT	HR*	95% CI FOR HR	P VALUE
acute GI	0.98	(0.96 – 1.01)	0.15
acute GU	1.01	(1.00 – 1.01)	0.20
late GI	1.00	(0.98 – 1.01)	0.59
late GU	0.99	(0.97 – 1.00)	0.16

* REFERENCE POINT-RT

TABLE S5. ASSOCIATION BETWEEN \geq G2 TOXICITY OCCURRENCE AND RADIOTHERAPY MODALITY USED

\geq G2 TOXICITY IN DYNAMIC VS STATIC RT METHOD	HR	95% CI FOR HR	P VALUE
acute GI	0.69	(0.29 – 1.66)	0.41
acute GU	1.68	(0.70 – 4.01)	0.24
late GI	1.50	(0.51 – 4.44)	0.46
late GU	0.91	(0.46 – 1.82)	0.79

Dynamic: IMRT, VMAT, Tomotherapy
Static: 3DCRT, 3DCRT+VMAT, 3DCRT+IMRT

TABLE S6. CLINICAL DESCRIPTION OF THE STUDY GROUP

≥G2 TOXICITY	CARDIOVASCULAR DISEASES		DIABETES		HAEMORRHOIDS		HT BEFORE RT		R1 SURGICAL MARGIN	
	OR (95% CI)	P VALUE	OR (95% CI)	P VALUE	OR (95% CI)	P VALUE	OR (95% CI)	P VALUE	OR (95% CI)	P VALUE
acute GI	0.88 (0.35- 2.23)	0.978	1.53 (0.32- 7.37)	0.639	4.81 (0.82- 28.08)	0.115	1.15 (0.48- 2.75)	0.746	1.1 (0.46- 2.63)	0.998
acute GU	1.56 (0.73- 3.32)	0.335	0.79 (0.17- 3.69)	1	5.16 (1.0- 26.76)	0.065	1.44 (0.71- 2.90)	0.310	1.28 (0.6- 2.72)	0.658
late GI	0.57 (0.22- 1.48)	0.357	0.26 (0.02- 4.61)	0.371	1.65 (0.18- 14.9)	0.508	0.71 (0.28- 1.83)	0.479	1.07 (0.42- 2.73)	0.929
late GU	1.02 (0.5- 2.09)	0.952	2.27 (0.71- 7.23)	0.28	4.03 (0.78- 20.82)	0.106	0.96 (0.48- 1.95)	0.919	1.34 (0.65- 2.77)	0.533

GI – gastrointestinal; GU – genitourinary; OR – odds ratio; CI – confidence interval